By Hillary Smith
University of Kentucky

Researchers at the University of Kentucky are part of a groundbreaking clinical trial exploring the use of medical marijuana in managing symptoms of late-stage dementia.

The National Institutes of Health-funded and U.S. Food and Drug Administration-approved LiBBY Study examines the potential benefits of cannabis-derived treatments for addressing agitation and discomfort in patients with advanced dementia, a population with limited palliative care options.

Dr. Greg Jicha, a neurologist and director of clinical trials at UK’s Sanders-Brown Center on Aging, says there is a pressing need for alternative treatments.“Until we find a cure for dementias, there will always be a stage where the focus shifts to comfort and quality of life,” he said. “Unfortunately, our current methods — such as sedatives and antipsychotics — often come with significant side effects. We need options that allow patients to remain alert, engaged and cared for at home or in skilled facilities.”

Dementia not only takes an emotional toll on patients, but on their families. Jicha says through his decades of work in the field that is one of the most difficult aspects of the disease.“There’s nothing more painful to family members than watching their loved one with dementia agitated, fearful or frightful,” he said. “It really is torture to family members.”

This profound distress often leaves families feeling helpless as they witness a loved one’s struggle with behaviors that can disrupt care and quality of life.

By exploring the potential of medical marijuana to alleviate these symptoms, the study aims to offer a new avenue of hope and relief for both patients and their caregivers.

The LiBBY Study is named after a late-stage dementia patient whose lack of treatment options for agitation symptoms motivated the search for potential alternatives, like medical marijuana. The study aims to build evidence-based knowledge about the effects of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, on dementia symptoms. THC and CBD are compounds found in the cannabis plant.

“We know that cannabinoid receptors in the brain are tied to emotional regulation,” Jicha said. “This could be an opportunity to bring peace and even improve interactions between patients and their families in the final stages of life.”

The research aligns closely with the expanding role of palliative care at UK, an area spearheaded by Dr. Jessica McFarlin, division chief of UK HealthCare’s Palliative and Supportive Care.“This study is not only about dementia alone but is also about advancing palliative care as a science,” McFarlin said. “We need evidence-based treatments to ensure we’re providing the highest quality of care, even in those final chapters.”

For families, the study offers a structured, monitored and science-driven alternative to self-medication.

“Many families are trying CBD or driving across state lines for medical marijuana without knowing its safety or effectiveness,” McFarlin said. “This trial reassures them that there’s a scientific foundation behind what they’re doing.”

Balancing innovation and safety

The trial offers participants access to THC and CBD through an open-label extension after an initial randomization phase, ensuring all enrolled patients can benefit from the study’s findings. It is also one of the first studies to run under Kentucky’s recent steps toward legalizing medical marijuana.

“Patients with late-stage dementia don’t have to wait for state-level legalization,” Jicha noted. “They can gain access now through this study.”

As the newly enacted medical marijuana law continues to roll out across Kentucky, dementia is not one of the six qualifying medical conditions approved for use.

Researchers are optimistic that the findings of the LiBBY Study could pave the way for dementia to be formally recognized as a medical condition for which cannabis can be prescribed. By building a strong foundation of evidence, the study aims to influence policy changes that would allow patients and their caregivers greater access to cannabis-derived treatments.

“Our hope is that this research will demonstrate the safety and effectiveness of medical marijuana for managing dementia symptoms,” Jicha said. “This could be a turning point in how we approach palliative care for some of the most vulnerable individuals in our society.”

Researchers believe UK is uniquely situated to lead an innovative study of this kind having the University of Kentucky Cannabis Center as a vital resource. The center was established by Kentucky House Bill 604 to advance the study of cannabis and its derivatives and determine the risk/benefit profile for select medical conditions.

“The establishment of the UK Cannabis Center provides us with access to cutting-edge research, expertise and infrastructure that enhance our ability to explore medical marijuana’s potential,” Jicha said. “This collaboration strengthens our efforts to ensure that the science driving this study is rigorous and impactful.”

A legacy of hope and growth

The study’s namesake, Libby, serves as a poignant reminder of the human impact of these medical advancements. Her case embodies the trial’s mission: to provide patients with dignity, comfort and relief in their final chapters.

“This approach could have been transformational for Libby and her family,” Jicha said. “It’s about giving families options and the confidence that their loved ones are receiving the best possible care.”

With recruitment underway and promising preliminary research, the LiBBY Study marks a significant step forward in dementia care and the broader field of palliative medicine.“This is just the beginning,” McFarlin said. “If this trial is successful, it could open doors for using medical marijuana in other end-of-life conditions, offering more choices and hope for patients and families alike.”

For more information on the study, click here.